Tracking the evolution of therapy-related myeloid neoplasms using chemotherapy signatures
Patients treated with cytotoxic therapies, including autologous stem cell transplantation, are at risk for developing therapy-related myeloid neoplasms (tMN). Preleukemic clones (ie, clonal hematopoiesis [CH]) are detectable years before the development of these aggressive malignancies, although the...
Uloženo v:
| Vydáno v: | Blood Ročník 141; číslo 19; s. 2359 |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
United States
11.05.2023
|
| Témata: | |
| ISSN: | 1528-0020, 1528-0020 |
| On-line přístup: | Zjistit podrobnosti o přístupu |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Patients treated with cytotoxic therapies, including autologous stem cell transplantation, are at risk for developing therapy-related myeloid neoplasms (tMN). Preleukemic clones (ie, clonal hematopoiesis [CH]) are detectable years before the development of these aggressive malignancies, although the genomic events leading to transformation and expansion are not well defined. Here, by leveraging distinctive chemotherapy-associated mutational signatures from whole-genome sequencing data and targeted sequencing of prechemotherapy samples, we reconstructed the evolutionary life-history of 39 therapy-related myeloid malignancies. A dichotomy was revealed, in which neoplasms with evidence of chemotherapy-induced mutagenesis from platinum and melphalan were hypermutated and enriched for complex structural variants (ie, chromothripsis), whereas neoplasms with nonmutagenic chemotherapy exposures were genomically similar to de novo acute myeloid leukemia. Using chemotherapy-associated mutational signatures as temporal barcodes linked to discrete clinical exposure in each patient's life, we estimated that several complex events and genomic drivers were acquired after chemotherapy was administered. For patients with prior multiple myeloma who were treated with high-dose melphalan and autologous stem cell transplantation, we demonstrate that tMN can develop from either a reinfused CH clone that escapes melphalan exposure and is selected after reinfusion, or from TP53-mutant CH that survives direct myeloablative conditioning and acquires melphalan-induced DNA damage. Overall, we revealed a novel mode of tMN progression that is not reliant on direct mutagenesis or even exposure to chemotherapy. Conversely, for tMN that evolve under the influence of chemotherapy-induced mutagenesis, distinct chemotherapies not only select preexisting CH but also promote the acquisition of recurrent genomic drivers. |
|---|---|
| AbstractList | Patients treated with cytotoxic therapies, including autologous stem cell transplantation, are at risk for developing therapy-related myeloid neoplasms (tMN). Preleukemic clones (ie, clonal hematopoiesis [CH]) are detectable years before the development of these aggressive malignancies, although the genomic events leading to transformation and expansion are not well defined. Here, by leveraging distinctive chemotherapy-associated mutational signatures from whole-genome sequencing data and targeted sequencing of prechemotherapy samples, we reconstructed the evolutionary life-history of 39 therapy-related myeloid malignancies. A dichotomy was revealed, in which neoplasms with evidence of chemotherapy-induced mutagenesis from platinum and melphalan were hypermutated and enriched for complex structural variants (ie, chromothripsis), whereas neoplasms with nonmutagenic chemotherapy exposures were genomically similar to de novo acute myeloid leukemia. Using chemotherapy-associated mutational signatures as temporal barcodes linked to discrete clinical exposure in each patient's life, we estimated that several complex events and genomic drivers were acquired after chemotherapy was administered. For patients with prior multiple myeloma who were treated with high-dose melphalan and autologous stem cell transplantation, we demonstrate that tMN can develop from either a reinfused CH clone that escapes melphalan exposure and is selected after reinfusion, or from TP53-mutant CH that survives direct myeloablative conditioning and acquires melphalan-induced DNA damage. Overall, we revealed a novel mode of tMN progression that is not reliant on direct mutagenesis or even exposure to chemotherapy. Conversely, for tMN that evolve under the influence of chemotherapy-induced mutagenesis, distinct chemotherapies not only select preexisting CH but also promote the acquisition of recurrent genomic drivers. Patients treated with cytotoxic therapies, including autologous stem cell transplantation, are at risk for developing therapy-related myeloid neoplasms (tMN). Preleukemic clones (ie, clonal hematopoiesis [CH]) are detectable years before the development of these aggressive malignancies, although the genomic events leading to transformation and expansion are not well defined. Here, by leveraging distinctive chemotherapy-associated mutational signatures from whole-genome sequencing data and targeted sequencing of prechemotherapy samples, we reconstructed the evolutionary life-history of 39 therapy-related myeloid malignancies. A dichotomy was revealed, in which neoplasms with evidence of chemotherapy-induced mutagenesis from platinum and melphalan were hypermutated and enriched for complex structural variants (ie, chromothripsis), whereas neoplasms with nonmutagenic chemotherapy exposures were genomically similar to de novo acute myeloid leukemia. Using chemotherapy-associated mutational signatures as temporal barcodes linked to discrete clinical exposure in each patient's life, we estimated that several complex events and genomic drivers were acquired after chemotherapy was administered. For patients with prior multiple myeloma who were treated with high-dose melphalan and autologous stem cell transplantation, we demonstrate that tMN can develop from either a reinfused CH clone that escapes melphalan exposure and is selected after reinfusion, or from TP53-mutant CH that survives direct myeloablative conditioning and acquires melphalan-induced DNA damage. Overall, we revealed a novel mode of tMN progression that is not reliant on direct mutagenesis or even exposure to chemotherapy. Conversely, for tMN that evolve under the influence of chemotherapy-induced mutagenesis, distinct chemotherapies not only select preexisting CH but also promote the acquisition of recurrent genomic drivers.Patients treated with cytotoxic therapies, including autologous stem cell transplantation, are at risk for developing therapy-related myeloid neoplasms (tMN). Preleukemic clones (ie, clonal hematopoiesis [CH]) are detectable years before the development of these aggressive malignancies, although the genomic events leading to transformation and expansion are not well defined. Here, by leveraging distinctive chemotherapy-associated mutational signatures from whole-genome sequencing data and targeted sequencing of prechemotherapy samples, we reconstructed the evolutionary life-history of 39 therapy-related myeloid malignancies. A dichotomy was revealed, in which neoplasms with evidence of chemotherapy-induced mutagenesis from platinum and melphalan were hypermutated and enriched for complex structural variants (ie, chromothripsis), whereas neoplasms with nonmutagenic chemotherapy exposures were genomically similar to de novo acute myeloid leukemia. Using chemotherapy-associated mutational signatures as temporal barcodes linked to discrete clinical exposure in each patient's life, we estimated that several complex events and genomic drivers were acquired after chemotherapy was administered. For patients with prior multiple myeloma who were treated with high-dose melphalan and autologous stem cell transplantation, we demonstrate that tMN can develop from either a reinfused CH clone that escapes melphalan exposure and is selected after reinfusion, or from TP53-mutant CH that survives direct myeloablative conditioning and acquires melphalan-induced DNA damage. Overall, we revealed a novel mode of tMN progression that is not reliant on direct mutagenesis or even exposure to chemotherapy. Conversely, for tMN that evolve under the influence of chemotherapy-induced mutagenesis, distinct chemotherapies not only select preexisting CH but also promote the acquisition of recurrent genomic drivers. |
| Author | Park, Jae H Usmani, Saad Watts, Justin Bolton, Kelly Diamond, Benjamin Landau, Heather Zhang, Yanming Nimer, Stephen Coffey, David Roshal, Mikhail Maclachlan, Kylee Ossa, Juan Arango McPherson, Andrew Ganesh, Karuna Sekeres, Mikkael A Jahn, Jacob Papaemmanuil, Elli Boyle, Eileen Morgan, Gareth Bolli, Niccolò Landgren, Ola Lesokhin, Alexander Chung, David J Taylor, Justin Affer, Maurizio Totiger, Tulasigeri M Ziccheddu, Bachisio Tyner, Jeffrey Chandhok, Namrata Maura, Francesco Ho, Caleb Cimmino, Luisa Lu, Sydney X |
| Author_xml | – sequence: 1 givenname: Benjamin orcidid: 0000-0002-8638-9365 surname: Diamond fullname: Diamond, Benjamin organization: Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL – sequence: 2 givenname: Bachisio surname: Ziccheddu fullname: Ziccheddu, Bachisio organization: Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL – sequence: 3 givenname: Kylee orcidid: 0000-0001-7873-4854 surname: Maclachlan fullname: Maclachlan, Kylee organization: Division of Myeloma, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY – sequence: 4 givenname: Justin orcidid: 0000-0003-4407-6325 surname: Taylor fullname: Taylor, Justin organization: Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL – sequence: 5 givenname: Eileen orcidid: 0000-0001-8791-1744 surname: Boyle fullname: Boyle, Eileen organization: Myeloma Research Program, New York University Langone, Perlmutter Cancer Center, New York, NY – sequence: 6 givenname: Juan Arango orcidid: 0000-0003-1109-6178 surname: Ossa fullname: Ossa, Juan Arango organization: Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY – sequence: 7 givenname: Jacob orcidid: 0000-0003-0745-7049 surname: Jahn fullname: Jahn, Jacob organization: Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL – sequence: 8 givenname: Maurizio surname: Affer fullname: Affer, Maurizio organization: Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL – sequence: 9 givenname: Tulasigeri M orcidid: 0000-0002-4262-4458 surname: Totiger fullname: Totiger, Tulasigeri M organization: Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL – sequence: 10 givenname: David orcidid: 0000-0003-3544-8836 surname: Coffey fullname: Coffey, David organization: Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL – sequence: 11 givenname: Namrata orcidid: 0000-0002-7464-4509 surname: Chandhok fullname: Chandhok, Namrata organization: Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL – sequence: 12 givenname: Justin surname: Watts fullname: Watts, Justin organization: Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL – sequence: 13 givenname: Luisa orcidid: 0000-0002-4218-582X surname: Cimmino fullname: Cimmino, Luisa organization: Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL – sequence: 14 givenname: Sydney X surname: Lu fullname: Lu, Sydney X organization: Division of Hematology, Stanford Hospital and Clinics, Stanford University, Stanford, CA – sequence: 15 givenname: Niccolò orcidid: 0000-0002-1018-5139 surname: Bolli fullname: Bolli, Niccolò organization: Hematology Unit, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy – sequence: 16 givenname: Kelly surname: Bolton fullname: Bolton, Kelly organization: Division of Oncology, Washington University School of Medicine, St. Louis, MO – sequence: 17 givenname: Heather orcidid: 0000-0002-3152-1189 surname: Landau fullname: Landau, Heather organization: Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY – sequence: 18 givenname: Jae H surname: Park fullname: Park, Jae H organization: Department of Medicine, Memorial Hospital, Memorial Sloan Kettering Cancer Center, New York, NY – sequence: 19 givenname: Karuna surname: Ganesh fullname: Ganesh, Karuna organization: Department of Medicine, Memorial Hospital, Memorial Sloan Kettering Cancer Center, New York, NY – sequence: 20 givenname: Andrew orcidid: 0000-0002-5654-5101 surname: McPherson fullname: McPherson, Andrew organization: Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY – sequence: 21 givenname: Mikkael A surname: Sekeres fullname: Sekeres, Mikkael A organization: Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL – sequence: 22 givenname: Alexander orcidid: 0000-0001-9321-702X surname: Lesokhin fullname: Lesokhin, Alexander organization: Division of Myeloma, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY – sequence: 23 givenname: David J surname: Chung fullname: Chung, David J organization: Adult Bone Marrow Transplant Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY – sequence: 24 givenname: Yanming surname: Zhang fullname: Zhang, Yanming organization: Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY – sequence: 25 givenname: Caleb orcidid: 0000-0001-5448-4635 surname: Ho fullname: Ho, Caleb organization: Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY – sequence: 26 givenname: Mikhail surname: Roshal fullname: Roshal, Mikhail organization: Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY – sequence: 27 givenname: Jeffrey surname: Tyner fullname: Tyner, Jeffrey organization: Division of Hematology and Medical Oncology, Oregon Health & Science University, Portland, OR – sequence: 28 givenname: Stephen surname: Nimer fullname: Nimer, Stephen organization: Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL – sequence: 29 givenname: Elli surname: Papaemmanuil fullname: Papaemmanuil, Elli organization: Department of Epidemiology and Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY – sequence: 30 givenname: Saad surname: Usmani fullname: Usmani, Saad organization: Division of Myeloma, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY – sequence: 31 givenname: Gareth surname: Morgan fullname: Morgan, Gareth organization: Myeloma Research Program, New York University Langone, Perlmutter Cancer Center, New York, NY – sequence: 32 givenname: Ola orcidid: 0000-0001-6485-4839 surname: Landgren fullname: Landgren, Ola organization: Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL – sequence: 33 givenname: Francesco orcidid: 0000-0002-5017-1620 surname: Maura fullname: Maura, Francesco organization: Sylvester Comprehensive Cancer Center, University of Miami, Miami, FL |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/36626250$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNkLtPwzAQxi1URB-wMyGPLCm240cyooqXVImlDEyRY1_agBMHO0HKf08qisR0351-9-m7W6JZ61tA6JqSNaUZuyud93bNCGNkajk_QwsqWJYQwsjsn56jZYwfhFCeMnGB5qmUTDJBFuh9F7T5rNs97g-A4du7oa99i311HATdjUkAp3uwuBnB-driFnzndGwiHuJx0Ryg8ScYx3rf6n4IEC_ReaVdhKtTXaG3x4fd5jnZvj69bO63iUlz1ifGplTmnIOwKjeZVqCFJcCUrHJleMVzY7kQkueqlCCMoSQrNSiqAJhWGVuh21_fLvivAWJfNHU04Jyegg6xmJzSdDo7yyf05oQOZQO26ELd6DAWf-9gP3rbZiU |
| CitedBy_id | crossref_primary_10_1007_s00204_024_03898_w crossref_primary_10_1038_s41467_024_50384_z crossref_primary_10_1038_s41375_024_02258_y crossref_primary_10_1016_j_canlet_2024_216767 crossref_primary_10_1159_000536152 crossref_primary_10_1080_10428194_2024_2376166 crossref_primary_10_3389_fonc_2024_1400461 crossref_primary_10_1007_s11912_024_01537_2 crossref_primary_10_1038_s41409_024_02462_5 crossref_primary_10_1038_s41588_025_02292_1 crossref_primary_10_1172_JCI180069 crossref_primary_10_1080_07853890_2024_2329132 |
| ContentType | Journal Article |
| Copyright | 2023 by The American Society of Hematology. |
| Copyright_xml | – notice: 2023 by The American Society of Hematology. |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1182/blood.2022018244 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine Chemistry Biology Anatomy & Physiology |
| EISSN | 1528-0020 |
| ExternalDocumentID | 36626250 |
| Genre | Research Support, Non-U.S. Gov't Journal Article Research Support, N.I.H., Extramural |
| GrantInformation_xml | – fundername: NCI NIH HHS grantid: U54 CA224019 – fundername: NCI NIH HHS grantid: P30 CA008748 – fundername: NCI NIH HHS grantid: P30 CA240139 |
| GroupedDBID | --- -~X .55 0R~ 23N 2WC 34G 39C 4.4 53G 5GY 5RE 5VS 6J9 AAEDW AALRI AAXUO AAYWO ABOCM ACGFO ACVFH ADBBV ADCNI ADVLN AENEX AEUPX AFETI AFOSN AFPUW AGCQF AIGII AITUG AKBMS AKRWK AKYEP ALMA_UNASSIGNED_HOLDINGS AMRAJ BAWUL BTFSW CGR CS3 CUY CVF DIK DU5 E3Z EBS ECM EFKBS EIF EJD EX3 F5P FDB FRP GS5 GX1 H13 IH2 K-O KQ8 L7B LSO MJL N9A NPM OK1 P2P R.V RHI ROL SJN THE TR2 TWZ W2D W8F WH7 WOQ WOW X7M YHG YKV 7X8 |
| ID | FETCH-LOGICAL-c392t-cd316944e5d79c8a7ea5d0e276f97c4f49cd4556497b6e5cc108bae717ee2a782 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 37 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001005503400001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1528-0020 |
| IngestDate | Thu Oct 02 10:31:19 EDT 2025 Mon Jul 21 05:56:30 EDT 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 19 |
| Language | English |
| License | 2023 by The American Society of Hematology. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c392t-cd316944e5d79c8a7ea5d0e276f97c4f49cd4556497b6e5cc108bae717ee2a782 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| ORCID | 0000-0003-4407-6325 0000-0002-1018-5139 0000-0002-8638-9365 0000-0003-3544-8836 0000-0001-8791-1744 0000-0001-6485-4839 0000-0002-4262-4458 0000-0002-7464-4509 0000-0001-7873-4854 0000-0003-1109-6178 0000-0002-5654-5101 0000-0002-4218-582X 0000-0003-0745-7049 0000-0001-5448-4635 0000-0002-3152-1189 0000-0001-9321-702X 0000-0002-5017-1620 |
| OpenAccessLink | https://www.ncbi.nlm.nih.gov/pmc/articles/10273163 |
| PMID | 36626250 |
| PQID | 2763332589 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2763332589 pubmed_primary_36626250 |
| PublicationCentury | 2000 |
| PublicationDate | 2023-05-11 |
| PublicationDateYYYYMMDD | 2023-05-11 |
| PublicationDate_xml | – month: 05 year: 2023 text: 2023-05-11 day: 11 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Blood |
| PublicationTitleAlternate | Blood |
| PublicationYear | 2023 |
| References | 37166926 - Blood. 2023 May 11;141(19):2292-2293 |
| References_xml | – reference: 37166926 - Blood. 2023 May 11;141(19):2292-2293 |
| SSID | ssj0014325 |
| Score | 2.580606 |
| Snippet | Patients treated with cytotoxic therapies, including autologous stem cell transplantation, are at risk for developing therapy-related myeloid neoplasms (tMN).... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 2359 |
| SubjectTerms | Antineoplastic Agents - pharmacology Hematopoietic Stem Cell Transplantation - adverse effects Humans Leukemia, Myeloid, Acute - drug therapy Leukemia, Myeloid, Acute - genetics Leukemia, Myeloid, Acute - pathology Melphalan Neoplasms, Second Primary - chemically induced Neoplasms, Second Primary - genetics Transplantation, Autologous - adverse effects |
| Title | Tracking the evolution of therapy-related myeloid neoplasms using chemotherapy signatures |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/36626250 https://www.proquest.com/docview/2763332589 |
| Volume | 141 |
| WOSCitedRecordID | wos001005503400001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LSyQxEC5c3VUv7u74fpGFZW_BfiSd5CQqihcHDyvMnoZ0UhHB6VFbhfn3VjLdeFoQvDR9aUjSldRXVV_lA_jtVF77ECrugvZc6Ay5RmXiNa61dzqzQddJbEINh3o0Mtddwq3taJX9mZgOaj91MUd-VNBGKMtCanP88MijalSsrnYSGl9gqSQoE61ajd6rCKJMoqvkojSPuKgvU-riKNHCKTwsyAFqcnH_B5jJ0Vx8_-wQf8BaBzHZydwmfsICNgNYP2kovJ7M2B-WSJ8pmz6Ab6f928pZL_02gOWrruK-Dv_ImbmYTmeEFBm-dpbKpoHNW7dmPLXDoGeTGd5P7zxrIindtpOWRVL9LSOzmHR9XjMW-SLpLtF2A24uzv-eXfJOjoE7AlHP3Pkyr4wQKL0yTluFVvoMadbBKCeCMM4LKSthVF2hdC7PdG2R4kXEwhIS2YTFZtrgNrBMh8rJoq4DOqFR1rYySlqCCiHHYNUO_OpXeExTjzUMS4N_acfva7wDW_PfNH6Y38sxLiuKzgjS7X7g6z1YjcLxkQeQ5_uwFGiz4wF8da_Pd-3TYbIjeg6vr94AFkfVNA |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Tracking+the+evolution+of+therapy-related+myeloid+neoplasms+using+chemotherapy+signatures&rft.jtitle=Blood&rft.au=Diamond%2C+Benjamin&rft.au=Ziccheddu%2C+Bachisio&rft.au=Maclachlan%2C+Kylee&rft.au=Taylor%2C+Justin&rft.date=2023-05-11&rft.issn=1528-0020&rft.eissn=1528-0020&rft.volume=141&rft.issue=19&rft.spage=2359&rft_id=info:doi/10.1182%2Fblood.2022018244&rft.externalDBID=NO_FULL_TEXT |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1528-0020&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1528-0020&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1528-0020&client=summon |